S&P 500 7718.60 -0.38%
NASDAQ 26506.99 -0.29%
TASI 11024.73 -0.40%
Oil (WTI) 91.48 +0.00%
Oil (Brent) 96.28 +0.00%
VIX 15.30 +5.30%
Gold 4476.60 +0.00%
USD/SAR 3.76 +0.02%

CRISPR Therapeutics AG

CRSP · Healthcare · · USD
55.79 USD
0.00 (-1.24%)
● Updated 2026-09-07 19:37 Saudi Time ↻ Refresh
Short-term Mid-term Long-term

Fahodi Score BUY Short-term (Swing)

68
/ 100
Technical 75
Trend & RS 69
Momentum 66
Fundamental (0%) 33
Macro 64
Liquidity 34
ComponentScoreWeight
Technical 75.0 40%
Trend & RS 69.4 20%
Momentum 65.8 20%
Fundamental 33.3 0%
Macro 64.4 15%
Liquidity 33.5 5%

Trade Setup

Entry 55.79
Stop Loss 50.69 (9.1%)
Target 1 (1:1) 60.89 (+9.1%)
Target 2 (2:1) 65.99 (+18.3%)
ATR(14) 2.55 (4.6%)
Risk per Share 5.10
Reward:Risk 2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor Score Z Bar
Value 72.8 +0.91
Momentum 65.8 +0.63
Quality 40.0 -0.40
Composite 59.5

Quality Scores

Piotroski F-Score 3 /9 — Weak
1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover
Altman Z-Score Insufficient Data

Valuation vs Peers Undervalued

MetricStockSectorvs Peers
P/E Ratio N/A 22.0 Inline
P/B Ratio 3.1 4.0 Below

Comparing against Healthcare median multiples.

Trading at a discount to sector peers — potential value opportunity.

Position Sizing — Kelly Criterion

4.5%
Recommended Size
44.77%
Full Kelly
22.38%
Half Kelly
5.0%
Max Cap (Moderate)

Kelly inputs derived from quant score 68/100. Estimated win rate 61%, avg win 9.1%, avg loss 3.6%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

BEAR Regime: BEAR (20% confidence) — position size reduced 10%

Signal Summary STRONG BUY

3
Bullish Signals
1
Bearish Signals
50.7
RSI(14)
1.1944
MACD

Relative Strength (RS) NEUTRAL

48
/ 99
RS Rating
O'Neil filter: <80
RS vs SPY → FLAT (+2.9% vs SPY 3M)
RS vs Sector INLINE (Healthcare)
RS New High No (44d since high)
Sector Outperformance -0.1% (3M)
RS Line — stock / SPY (90 bars)
← older newer →
RS vs SPY 50-day SMA of RS
NEUTRAL: In line with the market — no strong outperformance or underperformance.

Technical Indicators

IndicatorValueSignal
Rsi 50.7 NEUTRAL
Macd 1.1944 BEARISH
Ma Cross 53.76 / 53.24 GOLDEN CROSS
Trend Short ABOVE SMA50
Trend Long ABOVE SMA200
Bollinger MIDDLE
Volume 0.63x NORMAL

Key Levels

LevelPrice
52-Week High78.48
Bollinger Upper61.45
SMA(200)53.24
SMA(50)53.76
SMA(20)56.55
Current Price55.79
Bollinger Lower51.66
52-Week Low44.12
ATR(14)2.55

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

ACCUMULATION A Confidence
33%
Selling Climax Buying Climax
Acc: 2.0  |  Dist: 2.0  |  Markup: 2.0  |  Markdown: 0.0

Volume Spread Analysis (last 5 bars)

DateSignalVolDescription
2026-08-31 Normal 0.98x Normal bar — no special VSA pattern
2026-09-01 Normal 0.62x Normal bar — no special VSA pattern
2026-09-02 Normal 0.64x Normal bar — no special VSA pattern
2026-09-03 Normal 1.04x Normal bar — no special VSA pattern
2026-09-04 Normal 0.63x Normal bar — no special VSA pattern

Ichimoku Cloud NEUTRAL

LineValueStatus
Tenkan-sen (9) 58.45 Above Kijun
Kijun-sen (26) 54.92 Base line
Senkou A 56.69 Leading span A
Senkou B 54.67 Leading span B
Cloud 54.67 – 56.69 Bullish (Green)
Price vs Cloud 55.79 Inside Cloud
Chikou Span 47.99 Bullish
Alignment Score 3/4 NEUTRAL

TTM Squeeze & Divergences

TTM Squeeze

SQUEEZE OFF No squeeze Momentum: BEARISH
BB: 51.66 – 61.45  |  KC: 52.62 – 60.49

Divergences (last 60 bars)

TypeIndicatorBars AgoStrength
Regular Bearish MACD 13

Anchored VWAP

VWAP: 53.16 Anchor: 2026-03-30 (52w Low) ABOVE AVWAP +4.9%

Heikin-Ashi Trend

WEAKLY BEARISH Full data via /api/advanced/CRSP

Valuation

MetricValue
Market Cap5.39B
P/E (TTM)N/A
Forward P/EN/A
P/B3.09
EPS-4.71

Financial Health

MetricValue
Revenue Growth10.4%
Profit MarginN/A
ROE-26.1%
Debt/Equity44.87
Current Ratio17.85
Dividend YieldN/A
Payout RatioN/A
Beta1.76

Trading Data

55.79
Open
55.79
Day High
55.79
Day Low
904.3K
Volume (0.6x avg)

Recent News (8)

Why Is Ultragenyx (RARE) Up 6.4% Since Last Earnings Report?
Zacks · 2026-09-03
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026
Motley Fool · 2026-09-02
CRISPR Therapeutics (CRSP) Stock Looks Fully Valued As CTX310 Data Impresses
Simply Wall St. · 2026-09-02
Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report?
Zacks · 2026-09-02
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
BioPharma Dive · 2026-09-02
Heart-Drug Breakthroughs Can’t Stop Biotech Stocks From Sliding
Barrons.com · 2026-09-01
Vertex Pharmaceuticals Up 15% in a Month: How to Play the Stock
Zacks · 2026-08-26
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
Zacks · 2026-08-24

Price Chart (90 Days)

Candlesticks (green=up, red=down) SMA 20 SMA 50 Bollinger Bands (upper/lower) Volume (green=buying, red=selling)
Powered by Fahodi Methodology. This is analytical output, not financial advice. Always do your own due diligence.  ·  Pipeline status  ·  Data: —